Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.

Yunzhen HU; Minjuan Zuo; Xiaojuan Wang; Rongrong Wang; Lu LI; Xiaoyang LU; Saiping Jiang

Return

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats.

Author: Yunzhen HU ¹ ; Minjuan ZUO ² ; Xiaojuan WANG ¹ ; Rongrong WANG ¹ ; Lu LI ¹ ; Xiaoyang LU ¹ ; Saiping JIANG ¹
Author Information

1. Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
2. Public Service Platform for the Evaluation of Innovative Drug Property, Hangzhou 311121, China.
Publication Type:Journal Article
MeSH: Animals; COVID-19/drug therapy*; Drug Interactions; Drug Therapy, Combination; Female; Indoles/pharmacokinetics*; Lopinavir/pharmacokinetics*; Male; Rats; Retrospective Studies; Ritonavir/pharmacokinetics*; SARS-CoV-2
From: Journal of Zhejiang University. Science. B 2021;22(7):599-602
CountryChina
Language:English
Abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing (January 2, 2021). Since there are no targeted therapies for COVID-19, the current focus is the repurposing of drugs approved for other uses. In some clinical trials, antiviral drugs such as remdesivir (Grein et al., 2020), lopinavir/ritonavir (LPV/r) (Cao et al., 2020), chloroquine (Gao et al., 2020), hydroxychloroquine (Gautret et al., 2020), arbidol (Wang et al., 2020), and favipiravir (Cai et al., 2020b) have shown efficacy in COVID-19 patients. LPV/r combined with arbidol, which is the basic regimen in some regional hospitals in China including Zhejiiang Province, has shown antiviral effects in COVID-19 patients (Guo et al., 2020; Xu et al., 2020). A retrospective cohort study also reported that this combination therapy showed better efficacy than LPV/r alone for the treatment of COVID-19 patients (Deng et al., 2020).